Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson City, NY, USA.
Methods Mol Biol. 2021;2279:241-253. doi: 10.1007/978-1-0716-1278-1_19.
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths in the United States. It is extremely difficult to treat, and its survival rate is low. Today, the most effective treatments are still those that implement the platinum anticancer drug cisplatin (CDDP) in combination with other drugs. We previously demonstrated that the naturally occurring compound phenethyl isothiocyanate (PEITC) could be used to sensitize NSCLC cells to CDDP. Furthermore, co-encapsulation of PEITC and CDDP in liposomes enhances their toxicity toward NSCLC cells. We have optimized a liposomal-PEITC-CDDP formulation and investigated its cytotoxicity. We determined that liposomal-PEITC-CDDP is much more toxic toward human NSCLC cell lines than it is toward human normal lung cell lines. In this chapter, we describe detailed methods for preparing liposomal-PEITC-CDDP and determining its cytotoxicity.
非小细胞肺癌（NSCLC）是美国癌症相关死亡的主要原因之一。它极难治疗，存活率低。目前，最有效的治疗方法仍然是将顺铂（CDDP）等抗癌药物与其他药物联合使用。我们之前的研究表明，天然化合物苯乙基异硫氰酸酯（PEITC）可用于使 NSCLC 细胞对 CDDP 敏感。此外，将 PEITC 和 CDDP 共包封在脂质体中可增强其对 NSCLC 细胞的毒性。我们已经优化了一种脂质体-PEITC-CDDP 制剂，并研究了其细胞毒性。我们发现，与人类正常肺细胞系相比，脂质体-PEITC-CDDP 对人 NSCLC 细胞系的毒性要大得多。在本章中，我们将详细介绍制备脂质体-PEITC-CDDP 并测定其细胞毒性的方法。
